These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 28489587

  • 1. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
    Tiedje V, Ting S, Herold T, Synoracki S, Latteyer S, Moeller LC, Zwanziger D, Stuschke M, Fuehrer D, Schmid KW.
    Oncotarget; 2017 Jun 27; 8(26):42613-42620. PubMed ID: 28489587
    [Abstract] [Full Text] [Related]

  • 2. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
    Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC.
    Endocrine; 2016 Dec 27; 54(3):733-741. PubMed ID: 27696251
    [Abstract] [Full Text] [Related]

  • 3. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
    Bonhomme B, Godbert Y, Perot G, Al Ghuzlan A, Bardet S, Belleannée G, Crinière L, Do Cao C, Fouilloux G, Guyetant S, Kelly A, Leboulleux S, Buffet C, Leteurtre E, Michels JJ, Tissier F, Toubert ME, Wassef M, Pinard C, Hostein I, Soubeyran I.
    Thyroid; 2017 May 27; 27(5):682-692. PubMed ID: 28351340
    [Abstract] [Full Text] [Related]

  • 4. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
    Jeon MJ, Chun SM, Kim D, Kwon H, Jang EK, Kim TY, Kim WB, Shong YK, Jang SJ, Song DE, Kim WG.
    Thyroid; 2016 May 27; 26(5):683-90. PubMed ID: 26980298
    [Abstract] [Full Text] [Related]

  • 5. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing.
    Duan H, Li Y, Hu P, Gao J, Ying J, Xu W, Zhao D, Wang Z, Ye J, Lizaso A, He Y, Wu H, Liang Z.
    Histopathology; 2019 Dec 27; 75(6):890-899. PubMed ID: 31230400
    [Abstract] [Full Text] [Related]

  • 6. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
    Qin Y, Wang JR, Wang Y, Iyer P, Cote GJ, Busaidy NL, Dadu R, Zafereo M, Williams MD, Ferrarotto R, Gunn GB, Wei P, Patel K, Hofmann MC, Cabanillas ME.
    Thyroid; 2021 Aug 27; 31(8):1235-1243. PubMed ID: 33599171
    [Abstract] [Full Text] [Related]

  • 7. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
    Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME.
    Thyroid; 2017 Jan 27; 27(1):81-87. PubMed ID: 27785980
    [Abstract] [Full Text] [Related]

  • 8. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N, Nucera C.
    J Clin Endocrinol Metab; 2015 Jan 27; 100(1):35-42. PubMed ID: 25347569
    [Abstract] [Full Text] [Related]

  • 9. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.
    Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.
    Head Neck; 2019 Jun 27; 41(6):1928-1934. PubMed ID: 30758123
    [Abstract] [Full Text] [Related]

  • 10. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
    Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, Rubinstein JC, Choi M, Kiss N, Nelson-Williams C, Mane S, Rimm DL, Prasad ML, Höög A, Zedenius J, Larsson C, Korah R, Lifton RP, Carling T.
    Hum Mol Genet; 2015 Apr 15; 24(8):2318-29. PubMed ID: 25576899
    [Abstract] [Full Text] [Related]

  • 11. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.
    Cancer; 2005 Jun 01; 103(11):2261-8. PubMed ID: 15880523
    [Abstract] [Full Text] [Related]

  • 12. Search for new genetic biomarkers in poorly differentiated and anaplastic thyroid carcinomas using next generation sequencing.
    Sykorova V, Dvorakova S, Vcelak J, Vaclavikova E, Halkova T, Kodetova D, Lastuvka P, Betka J, Vlcek P, Reboun M, Katra R, Bendlova B.
    Anticancer Res; 2015 Apr 01; 35(4):2029-36. PubMed ID: 25862857
    [Abstract] [Full Text] [Related]

  • 13. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
    Abe I, Lam AK.
    Curr Oncol Rep; 2021 Feb 13; 23(3):31. PubMed ID: 33582932
    [Abstract] [Full Text] [Related]

  • 14. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.
    Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD.
    Mol Cancer Ther; 2018 Jul 13; 17(7):1575-1584. PubMed ID: 29695638
    [Abstract] [Full Text] [Related]

  • 15. Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines.
    Woodward EL, Biloglav A, Ravi N, Yang M, Ekblad L, Wennerberg J, Paulsson K.
    Endocr Relat Cancer; 2017 May 13; 24(5):209-220. PubMed ID: 28235956
    [Abstract] [Full Text] [Related]

  • 16. Molecular therapeutics for anaplastic thyroid cancer.
    Pozdeyev N, Rose MM, Bowles DW, Schweppe RE.
    Semin Cancer Biol; 2020 Apr 13; 61():23-29. PubMed ID: 31991166
    [Abstract] [Full Text] [Related]

  • 17. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
    Deeken-Draisey A, Yang GY, Gao J, Alexiev BA.
    Hum Pathol; 2018 Dec 13; 82():140-148. PubMed ID: 30075157
    [Abstract] [Full Text] [Related]

  • 18. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
    Wu H, Sun Y, Ye H, Yang S, Lee SL, de las Morenas A.
    Pathol Oncol Res; 2015 Jul 13; 21(3):695-701. PubMed ID: 25588542
    [Abstract] [Full Text] [Related]

  • 19. Novel Recurrent Altered Genes in Chinese Patients With Anaplastic Thyroid Cancer.
    Zhang L, Ren Z, Su Z, Liu Y, Yang T, Cao M, Jiang Y, Tang Y, Chen H, Zhang W, Gong R, Wei T, Peng Y, Liu B, Zhang W, Yang L, Hu Y, Li Z, Zhu J, Xu H, Shu Y, Luo H.
    J Clin Endocrinol Metab; 2021 Mar 25; 106(4):988-998. PubMed ID: 33428730
    [Abstract] [Full Text] [Related]

  • 20. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
    Yoo SK, Song YS, Lee EK, Hwang J, Kim HH, Jung G, Kim YA, Kim SJ, Cho SW, Won JK, Chung EJ, Shin JY, Lee KE, Kim JI, Park YJ, Seo JS.
    Nat Commun; 2019 Jun 24; 10(1):2764. PubMed ID: 31235699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.